ロード中...
PCSK9 Inhibition: Insights From Clinical Trials and Future Prospects
In 2003, clinical observations led to the discovery of the involvement of proprotein convertase subtilisin/kexin type 9 (PCSK9) in lipid metabolism. Functional studies demonstrated that PCSK9 binds to the low-density lipoprotein (LDL) receptor directing it to its lysosomal degradation. Therefore, ca...
保存先:
| 出版年: | Front Physiol |
|---|---|
| 主要な著者: | , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Frontiers Media S.A.
2020
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7701092/ https://ncbi.nlm.nih.gov/pubmed/33304274 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fphys.2020.595819 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|